Pivotal readouts on deck as Takeda sees stagnant sales this year

Title

Takeda Prepares for Pivotal Phase 3 Readouts Amid Flat 2025 Sales Forecast

Takeda forecasts "broadly flat" sales and operating profit for fiscal year 2025, citing the final substantial headwinds from the loss of Vyvanse exclusivity and generics competition1.
The company labels FY2025 as a pivotal year, with significant investment in launch readiness for its late-stage drug pipeline1.
Takeda anticipates up to six new molecular entities in Phase 3 development during FY2025, with three major Phase 3 data readouts either recently completed or expected within the year1.
A positive Phase 3 readout for rusfertide in oncology was achieved in March 2025, and two additional Phase 3 readouts are expected in core therapeutic areas this fiscal year1 5.
Takeda aims for three regulatory filings in FY2025–FY2026, and five more by FY2029; six late-stage programs could collectively generate between $10 billion and $20 billion in peak revenues, supporting long-term growth3.
The company is balancing Growth & Launch Product momentum against patent expiry losses and is implementing cost efficiencies to drive operating profit1 3.
Takeda announced a new share buyback program of up to JPY 100 billion, reflecting confidence in future growth and a commitment to shareholder returns3.
A proposed dividend increase from JPY 196 to JPY 200 has been announced for shareholders1.